Low-Dose Pioglitazone in Patients With NASH (AIM 2)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 166 participants.

Also called NCT04501406

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 166 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04501406
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04501406. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-15 (actual); primary completion 2027-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Condition
Type 2 Diabetes Mellitus (T2DM)
Condition
Nonalcoholic Steatohepatitis
Intervention (Drug)
Pioglitazone
Intervention (Other)
Placebo
Lead sponsor
University of Florida (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04501406
Content hash
9f0d32d2d79ee0f7a8ed52f7091b7a01bc222c214a2b047624f9ce1c4fd6a92c